• Explore /
  • Poster
  • / Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Abstract Poster

Authors

Kathleen Moore

Kathleen N. Moore

Stephenson Cancer Center at the University of Oklahoma HSC and Sarah Cannon Research Institute, Oklahoma City, OK

Kathleen N. Moore , Setsuko K. Chambers , Erika Paige Hamilton , Lee-may Chen , Amit M. Oza , Sharad A. Ghamande , Gottfried E. Konecny , Steven C. Plaxe , Daniel Lewis Spitz , Jill J.J. Geenen , Tiffany A. Troso-Sandoval , Janiel M. Cragun , Esteban Rodrigo Imedio , Sanjeev Kumar , Ganesh M. Mugundu , Zhongwu Lai , Juliann Chmielecki , Suzanne Fields Jones , David R. Spigel , Karen Anne Cadoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02272790

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5513)

DOI

10.1200/JCO.2019.37.15_suppl.5513

Abstract #

5513

Poster Bd #

336

Abstract Disclosures

Similar Posters

First Author: Kathleen N. Moore

Poster

2019 ASCO Annual Meeting

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).

First Author: Haider Mahdi

First Author: Antonio Gonzalez-Martin

First Author: Lingying Wu